These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8697676)

  • 1. Therapy dose calculation in Graves' disease using early I-123 uptake measurements.
    Vemulakonda US; Atkins FB; Ziessman HA
    Clin Nucl Med; 1996 Feb; 21(2):102-5. PubMed ID: 8697676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of late (24-hour) radioactive iodine uptake using early (3-hour) uptake values in Japanese patients with Graves' disease.
    Osaki Y; Sakurai K; Arihara Z; Hata M; Fukazawa H
    Endocr J; 2012; 59(2):173-7. PubMed ID: 22095001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of radioiodine doses for 6-hr and 24-hour iodine-131 thyroid uptake values for Graves' hyperthyroidism.
    Horn-Lodewyk J
    Endocr J; 2019 Dec; 66(12):1047-1052. PubMed ID: 31391354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accuracy considerations when using early (four- or six-hour) radioactive iodine uptake to predict twenty-four-hour values for radioactive iodine dosage in the treatment of Graves' disease.
    Morris LF; Waxman AD; Braunstein GD
    Thyroid; 2000 Sep; 10(9):779-87. PubMed ID: 11041455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of the possibility of curing Graves' disease based on the desired reduction of thyroid mass (volume) as a consequence of 131I therapy: a speculative paper.
    Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
    Nucl Med Commun; 2006 May; 27(5):439-46. PubMed ID: 16609355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iodine-131 treatment of Graves' disease using modified early iodine-131 uptake measurements in therapy dose calculations.
    Hayes AA; Akre CM; Gorman CA
    J Nucl Med; 1990 Apr; 31(4):519-22. PubMed ID: 2324829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors for early hypothyroidism following the radioactive iodine therapy in Graves' disease patients.
    Hu RT; Liu DS; Li B
    BMC Endocr Disord; 2020 May; 20(1):76. PubMed ID: 32471411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative measurement of thyroid blood flow for differentiation of painless thyroiditis from Graves' disease.
    Ota H; Amino N; Morita S; Kobayashi K; Kubota S; Fukata S; Kamiyama N; Miyauchi A
    Clin Endocrinol (Oxf); 2007 Jul; 67(1):41-5. PubMed ID: 17437515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [F-qi-FDG PET of the thyroid gland in Graves' disease].
    Börner AR; Voth E; Wienhard K; Wagner R; Schicha H
    Nuklearmedizin; 1998; 37(7):227-33. PubMed ID: 9830612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioiodine uptake following iodine-131 therapy for Graves' disease: an early indicator of need for retreatment.
    Carpentier WR; Gilliland PF; Piziak VK; Petty FC; McConnell BG; Verdonk CA; Ibarra JD; Thompson JQ
    Clin Nucl Med; 1989 Jan; 14(1):15-8. PubMed ID: 2714035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re-establishment of normal radioactive iodine uptake reference range in the era of universal salt iodization in the Indian population.
    Ballal S; Soundararajan R; Bal C
    Indian J Med Res; 2017 Mar; 145(3):358-364. PubMed ID: 28749399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calculation of therapeutic activity of radioiodine in Graves' disease by means of Marinelli's formula, using technetium (
    Szumowski P; Mojsak M; Abdelrazek S; Sykała M; Amelian-Fiłonowicz A; Jurgilewicz D; Myśliwiec J
    Endocrine; 2016 Dec; 54(3):751-756. PubMed ID: 27553050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A simplified method for treating Graves' disease with radioactive 131I.
    Masri MT; Menne M; Rooney BL; Caplan RH
    Wis Med J; 1995 Jan; 94(1):21-5. PubMed ID: 7871797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iodine-131 uptake and turnover rate vary over short intervals in Graves' disease.
    Van Isselt JW; de Klerk JM; Koppeschaar HP; Van Rijk PP
    Nucl Med Commun; 2000 Jul; 21(7):609-16. PubMed ID: 10994662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of early (5 to 6 hours) iodine 123 uptake for diagnosis and treatment planning in Graves' disease.
    Hennessey JV; Berg LA; Ibrahim MA; Markert RJ
    Arch Intern Med; 1995 Mar; 155(6):621-4. PubMed ID: 7887758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calculation of the radioiodine dose for the treatment of Graves' hyperthyroidism: is more than seven-thousand rad target dose necessary?
    Bajnok L; Mezosi E; Nagy E; Szabo J; Sztojka I; Varga J; Galuska L; Leovey A
    Thyroid; 1999 Sep; 9(9):865-9. PubMed ID: 10524564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
    Berg GE; Michanek AM; Holmberg EC; Fink M
    J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discriminant factors affecting early outcome of radioiodine treatment for Graves' disease.
    Kung AW; Choi P; Lam KS; Pun KK; Wang C; Yeung RT
    Clin Radiol; 1990 Jul; 42(1):52-4. PubMed ID: 2390837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
    Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
    Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioactive iodine therapy in Graves' hyperthyroidism: a prospective study from a tertiary referral centre in north India.
    Sankar R; Sekhri T; Sripathy G; Walia RP; Jain SK
    J Assoc Physicians India; 2005 Jul; 53():603-6. PubMed ID: 16190128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.